Replies to post #130333 on Biotech Values

[oc631]

Moreover, there’s no reason why DEB025 can’t be an effective addend to a nuke-based regimen.

Sorry I didn't make myself clear. That's what I was suggesting here.

The drug could find a market after years of nuke/riba or nuke monotherapy but I would expect this to be very limited.